GLSI
Greenwich Lifesciences IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$311.87M
P/E Ratio
—
EPS
$-1.46
Beta
1.53
52W High
$34.10
52W Low
$7.78
50-Day MA
$26.41
200-Day MA
$15.63
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Greenwich Lifesciences Inc
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for breast and other HER2 / neu-expressing cancers. The company is headquartered in Stafford, Texas.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-19.58M |
| Operating Margin | 0.00% |
| Return on Equity | -543.00% |
| Return on Assets | -254.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.16 |
| Price-to-Book | 143.81 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -21.23 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $13.85M |
| Float | $6.57M |
| % Insiders | 50.71% |
| % Institutions | 10.79% |
Analyst Ratings
Consensus ($47.50 target)
2
BuyData last updated: 4/8/2026